• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Proposed FDA study will allow adoption, not euthanasia, of research dogs

November 30, 2018
dvm360, dvm360 January 2019, Volume 50, Issue 1

Parasiticide research aims to validate alternatives to use of animal subjects in some bioequivalence trials.

The U.S. Food and Drug Administration (FDA) recently released proposed research aiming to validate an alternative approach to bioequivalence studies for certain animal drugs. This would eliminate the need to use and later euthanize dogs in certain types of research, according to a release from the FDA.

The proposed study will collect blood samples from dogs that have been given two common antiparasitic drugs-ivermectin and praziquantel-to compare their bioequivalence. Ivermectin, which is used to treat heartworm, and praziquantel, a treatment for tapeworms, act both locally and systemically. According to the release, bioequivalence studies of antiparasitic drugs that act locally within the gastrointestinal tract have historically ended in euthanasia.

In this study, however, the bioequivalence of ivermectin and praziquantel will be measured by “in vitro dissolution compared to blood levels that indicate how the drug is dissolving in the body (also known as blood-level pharmacokinetics), with the goal of validating these laboratory-based alternative (i.e. surrogate) endpoints,” the release states.

None of the dogs in the study will be artificially infected, and they will receive regular preventive veterinary care until they are retired for adoption once the research concludes. The dogs will also undergo two months of socialization with FDA animal care staff before the study begins to get them used to being handled.

Advertisement

If the findings support the researchers' current hypothesis, the data will be made public so animal drug sponsors can apply it in designing in vitro studies, thus eliminating the need for animal subjects in some research. 

To read the white paper, click here.

The FDA is currently accepting public comments on the proposed study. To submit your comments, visit regulations.gov and type FDA-2018-N-3345 in the search box.

download issueDownload Issue: dvm360 January 2019

Related Content:

RegulatoryBreaking Newsdvm360 January 2019
The new Shreiber School of Veterinary Medicine breaks ground
The new Shreiber School of Veterinary Medicine breaks ground
Feed control officials reassert copper concentration guidelines
Feed control officials reassert copper concentration guidelines
Fentanyl combined with xylazine designated an emerging threat to the United States
Fentanyl combined with xylazine designated an emerging threat to the United States

Advertisement

Latest News

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

CityVet Celina opens in Prosper, Texas

View More Latest News
Advertisement